FTXH Performance — First Trust Nasdaq Pharmaceuticals ETF
Data updated: 2026-08-21
FTXH returned +16.34% year to date and +50.78% over one year to Jun 2026. Annualised returns are +15.00% over 3 years and +9.60% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $152, against $138 for the category, and to $151 over one year, against $137. Volatility over the past three years was 14.43% a year. In the 12 months to Jun 2026 the fund took in a net $13.4M, and assets reached $36.24M.
FTXH Growth of $100
What $100 invested in First Trust Nasdaq Pharmaceuticals ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | FTXH | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $151 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $152 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $158 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $197 | $182 |
FTXH Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +16.34% |
| 1 year | +50.78% |
| 3 years (annualised) | +15.00% |
| 5 years (annualised) | +9.60% |
FTXH Annual Returns
Calendar-year total returns of First Trust Nasdaq Pharmaceuticals ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +16.34% |
| 2025 | +24.04% |
| 2024 | +2.96% |
| 2023 | −1.41% |
| 2022 | +2.52% |
| 2021 | +6.10% |
| 2020 | +10.85% |
| 2019 (Jul–Dec) | +11.50% |
FTXH Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +3.0% | +5.0% | −3.5% | −1.4% | +3.5% | +9.1% | — | — | — | — | — | — |
| 2025 | +2.9% | +1.8% | −2.2% | −5.6% | −1.8% | +0.8% | +0.8% | +7.4% | +3.3% | +5.8% | +9.9% | −0.3% |
| 2024 | +1.5% | +2.5% | +1.2% | −7.2% | +2.4% | +2.9% | +4.9% | +3.9% | −2.4% | −2.1% | +0.5% | −4.5% |
| 2023 | +0.5% | −4.5% | −0.5% | +1.9% | −3.7% | +2.8% | +1.3% | +1.3% | −4.6% | −5.9% | +3.9% | +7.0% |
| 2022 | −4.3% | −2.7% | +5.9% | −1.7% | +1.8% | −0.4% | −0.4% | −6.1% | −2.8% | +10.3% | +6.1% | −1.9% |
| 2021 | +1.0% | −1.1% | −0.7% | +1.5% | −0.2% | +0.4% | +2.1% | +1.1% | −4.4% | +3.4% | −3.1% | +6.5% |
| 2020 | −2.3% | −8.3% | −7.8% | +14.6% | +4.1% | −0.8% | +3.1% | +4.7% | −2.9% | −2.9% | +7.8% | +3.3% |
| 2019 | — | — | — | — | — | — | −3.0% | −1.1% | +0.2% | +4.5% | +7.8% | +3.0% |
FTXH Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 14.43%
- 3-year Sharpe ratio: 0.73 (vs 4.5% risk-free rate)
- Best month: +9.88% (Nov 2025)
- Worst month: −7.25% (Apr 2024)
FTXH Fund Flows
Monthly money in and out of First Trust Nasdaq Pharmaceuticals ETF, from SEC Form N-PORT.
- 12-month net flow: $13.4M
- 12-month gross sales (incl. reinvestments): $15.2M
- Sales ÷ redemptions: 8.50×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $0 | $1.8M | −$1.8M |
| May 2026 | $1.7M | $0 | $1.7M |
| Apr 2026 | $3.4M | $0 | $3.4M |
| Mar 2026 | $0 | $0 | $0 |
| Feb 2026 | $5.3M | $0 | $5.3M |
| Jan 2026 | $1.7M | $0 | $1.7M |
| Dec 2025 | $1.7M | $0 | $1.7M |
| Nov 2025 | $0 | $0 | $0 |
| Oct 2025 | $1.5M | $0 | $1.5M |
| Sep 2025 | $0 | $0 | $0 |
| Aug 2025 | $0 | $0 | $0 |
| Jul 2025 | $0 | $0 | $0 |
FTXH Assets Under Management
Net assets of First Trust Nasdaq Pharmaceuticals ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $36.24M |
| 2026-03-31 | $29.18M |
| 2025-12-31 | $21.41M |
| 2025-09-30 | $15.69M |
| 2025-06-30 | $14.10M |
| 2025-03-31 | $15.14M |
| 2024-12-31 | $14.84M |
| 2024-09-30 | $17.30M |
| 2024-06-30 | $20.43M |
| 2024-03-31 | $21.00M |
| 2023-12-31 | $18.64M |
| 2023-09-29 | $20.46M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.